Role of LILRA3 in Ankylosing Spondylitis and Axial Psoriatic Patients

NCT05915676 | Unknown

• 1 other identifier: LILRA3 in AS, Axial psoriasis
• Study Type: observational
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

1. 1.To evaluate the frequency of LILRA3 in Ankylosing spondylitis and Axial psoriatic arthritis patients.
2. 2.To investigate the association of LILRA3 with Ankylosing spondylitis and Axial psoriatic arthritis disease activity and severity.

Conditions

Autoimmune Diseases

Outcome Measures

Primary Outcomes (1)

• LILRA3 in AS and Axial psoriatic arthritis patients.

  To evaluate the frequency of LILRA3 in Ankylosing spondylitis and Axial psoriatic arthritis patients.

  Baseline

Secondary Outcomes (1)

• Assosciation of LILRA3 with disease severity

  Baseline

Interventions

Leukocyte Immunoglobulin-like receptors A3 DIAGNOSTIC_TEST

Leucocyte immunoglobulin-like receptor A3 (LILRA3) belongs to a family of leucocyte receptors produced as a soluble molecule by monocytes and macrophages. (3) The function of LILRA3 remains obscure, but LILRA3 could bind to HLA class I molecules HLA-G and HLA- C (4) and may act as an antagonist on other LILRs or a soluble ligand to other receptors(5) Growing evidence shows that (LILRA3) is associated with many autoimmune disorders.(6) (7) The functional LILRA3 is a susceptibility factor for AS and axial psoriatic arthritis (axPsA) has not been investigated.

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Egyptian population

You may not qualify if:

• Individuals with other autoimmune diseases

Sponsors & Collaborators

• Assiut University: lead

Related Publications (4)

• Ryu M, Chen Y, Qi J, Liu J, Fan Z, Nam G, Shi Y, Cheng H, Gao GF. LILRA3 binds both classical and non-classical HLA class I molecules but with reduced affinities compared to LILRB1/LILRB2: structural evidence. PLoS One. 2011 Apr 29;6(4):e19245. doi: 10.1371/journal.pone.0019245.

  PMID: 21559424 BACKGROUND

• Wang R, Ward MM. Epidemiology of axial spondyloarthritis: an update. Curr Opin Rheumatol. 2018 Mar;30(2):137-143. doi: 10.1097/BOR.0000000000000475.

  PMID: 29227352 RESULT

• Poddubnyy D. Axial spondyloarthritis: is there a treatment of choice? Ther Adv Musculoskelet Dis. 2013 Feb;5(1):45-54. doi: 10.1177/1759720X12468658.

  PMID: 23514983 RESULT

• Norman PJ, Carey BS, Stephens HAF, Vaughan RW. DNA sequence variation and molecular genotyping of natural killer leukocyte immunoglobulin-like receptor, LILRA3. Immunogenetics. 2003 Jun;55(3):165-171. doi: 10.1007/s00251-003-0561-1. Epub 2003 May 16.

  PMID: 12750859 RESULT

MeSH Terms

Conditions

Autoimmune Diseases

Condition Hierarchy (Ancestors)

Immune System Diseases

Study Officials

• Zahraa Abou eleyoun, PHD

  Assiut University

  STUDY CHAIR

Central Study Contacts

Alaa Adel

CONTACT

+201124098363; alaa.adel27@yahoo.com

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Frequency Assessment of Leukocyte Immunoglobulin-like receptors A3 In Ankylosing Spondylitis And Axial Psoriatic Arthritis Patients

Study Record Dates

• First Submitted: June 14, 2023
• First Posted: June 23, 2023
• Study Start: July 1, 2023
• Primary Completion: June 1, 2024
• Study Completion: July 30, 2024
• Last Updated: June 23, 2023

Record last verified: 2023-06